All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Giampaolo Merlini, University of Pavia, Pavia, IT, about the latest advances in AL amyloidosis treatment.
Latest advances in AL amyloidosis treatment
During this year, three clinical trials evaluating combinations of different drugs in patients with AL amyloidosis have been concluded. Giampaolo Merlini discusses the promising results of these clinical trials, which contributed to improving patient care.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox